AnaptysBio, Inc. (NASDAQ:ANAB) Director Ecor1 Capital, Llc Purchases 65,184 Shares

AnaptysBio, Inc. (NASDAQ:ANAB) Director Ecor1 Capital, Llc purchased 65,184 shares of the firm’s stock in a transaction that occurred on Monday, December 30th. The shares were bought at an average price of $12.92 per share, with a total value of $842,177.28. Following the completion of the acquisition, the director now owns 7,860,180 shares of the company’s stock, valued at $101,553,525.60. This trade represents a 0.84 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Ecor1 Capital, Llc also recently made the following trade(s):

• On Thursday, January 2nd, Ecor1 Capital, Llc acquired 6,646 shares of AnaptysBio stock. The stock was acquired at an average price of $12.95 per share, with a total value of $86,065.70.

AnaptysBio Trading Up 0.9 %

ANAB traded up $0.12 during trading on Thursday, reaching $13.36. 465,990 shares of the company’s stock were exchanged, compared to its average volume of 390,740. The firm has a fifty day moving average price of $20.47 and a two-hundred day moving average price of $28.60. The stock has a market capitalization of $406.53 million, a PE ratio of -2.20 and a beta of -0.11. AnaptysBio, Inc. has a one year low of $12.51 and a one year high of $41.31.

AnaptysBio (NASDAQ:ANAB) last announced its earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.72) by $0.58. The business had revenue of $30.02 million during the quarter, compared to analyst estimates of $7.92 million. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. Sell-side analysts expect that AnaptysBio, Inc. will post -6.02 earnings per share for the current year.

Wall Street Analyst Weigh In

ANAB has been the subject of several recent analyst reports. Truist Financial decreased their target price on AnaptysBio from $30.00 to $20.00 and set a “hold” rating for the company in a research note on Wednesday, December 18th. Wells Fargo & Company reduced their price target on shares of AnaptysBio from $56.00 to $40.00 and set an “overweight” rating on the stock in a research report on Thursday, December 12th. Wedbush reaffirmed an “outperform” rating and issued a $40.00 target price (down previously from $42.00) on shares of AnaptysBio in a research note on Wednesday, December 11th. Guggenheim cut their price target on AnaptysBio from $90.00 to $36.00 and set a “buy” rating on the stock in a report on Thursday, December 12th. Finally, JPMorgan Chase & Co. decreased their target price on shares of AnaptysBio from $66.00 to $36.00 and set an “overweight” rating for the company in a research note on Thursday, December 19th. Four equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $41.45.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in ANAB. FMR LLC boosted its position in AnaptysBio by 15.3% in the third quarter. FMR LLC now owns 3,309,175 shares of the biotechnology company’s stock worth $110,857,000 after purchasing an additional 438,557 shares during the last quarter. Frazier Life Sciences Management L.P. boosted its holdings in AnaptysBio by 2.0% in the third quarter. Frazier Life Sciences Management L.P. now owns 2,209,189 shares of the biotechnology company’s stock valued at $74,008,000 after acquiring an additional 43,598 shares in the last quarter. Assenagon Asset Management S.A. lifted its stake in shares of AnaptysBio by 55.1% in the 3rd quarter. Assenagon Asset Management S.A. now owns 475,446 shares of the biotechnology company’s stock valued at $15,927,000 after purchasing an additional 168,813 shares during the period. Geode Capital Management LLC increased its stake in shares of AnaptysBio by 3.0% during the third quarter. Geode Capital Management LLC now owns 465,401 shares of the biotechnology company’s stock valued at $15,594,000 after purchasing an additional 13,336 shares in the last quarter. Finally, Jennison Associates LLC purchased a new position in AnaptysBio during the third quarter valued at $8,874,000.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.